DEF: Cosmos Health Inc. Schedules 2026 Annual Meeting

Cosmos Health Inc. has issued a proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections, auditor ratification, equity plan approval, and preferred stock issuance.

Summary

• Cosmos Health Inc. is holding its 2026 Annual Meeting of Stockholders on July 15, 2026, at its U.S. headquarters in Chicago, IL.
• The meeting agenda includes the election of six directors, ratification of the independent registered public accounting firm (RBSM LLP), approval of the 2026 Equity Incentive Plan, and approval for the designation and issuance of Series B Preferred Stock.
• Stockholders of record as of May 19, 2026, are entitled to vote.
• The company is providing proxy materials electronically and encourages stockholders to vote online, by mail, or in person.
• The Board of Directors unanimously recommends voting 'FOR' all proposals.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the ongoing financial losses and compliance issues (late filings), despite the routine nature of a proxy statement and the positive intent of the equity plan.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and fulfill corporate governance requirements.
• The proposed 2026 Equity Incentive Plan aims to attract and retain talent by aligning employee interests with shareholder value.
• The Series B Preferred Stock proposal is designed to assist in establishing a quorum at meetings, mitigating a potential operational risk.
• The company is making proxy materials readily available online to enhance stockholder access to information.

Negatives

• Several directors and officers, including the CEO, CFO, and other key personnel, failed to file Section 16(a) beneficial ownership reports on a timely basis for incentive shares granted on December 31, 2025. These filings are expected in May 2026.
• The company has a history of significant net losses, with $19,144,998 in 2025 and $16,183,018 in 2024.
• A significant allowance for doubtful accounts of $3.9 million was recorded against a loan receivable from Doc Pharma, indicating concerns about recoverability.
• An allowance of $194,215 was recorded against advance payments to Panagiotis Kozaris for share repurchases due to uncertainty of recovery.
• The company has no anti-hedging or anti-pledging policies for its directors and officers.

Risks

• Failure to obtain a quorum at shareholder meetings due to low retail investor engagement is a stated risk, which the Series B Preferred Stock aims to mitigate.
• The company has experienced significant net losses in recent years, indicating ongoing financial challenges.
• Related party transactions, particularly with Doc Pharma, involve substantial prepayments and receivables, with a significant allowance for doubtful accounts recorded against a loan to Doc Pharma, highlighting potential financial risks.
• The company has not implemented anti-hedging or anti-pledging policies, which could expose the company and its stakeholders to certain risks.
• The timely filing of Section 16(a) reports by key personnel has been an issue, suggesting potential weaknesses in compliance processes.

Future Outlook

The company is seeking stockholder approval for its 2026 Equity Incentive Plan, which is designed to attract and retain talent and align employee interests with shareholder value. The approval of Series B Preferred Stock is intended to ensure quorum at future meetings, mitigating operational risks associated with low shareholder participation.

Management Comments

• "Your vote is important. Whether or not you plan to attend the Annual Meeting, I hope you will vote as soon as possible."
• "We have elected to provide access to our proxy materials over the internet under the Securities and Exchange Commissions notice and access rules. We are constantly focused on improving the ways people connect with information and believe that providing our proxy materials over the internet increases the ability of our stockholders to connect with the information they need."
• "The Board believes that stock-based incentive awards play an important role in our success by encouraging and enabling our officers, employees, non-employee directors and consultants upon whose judgment, initiative and efforts we largely depend for the successful conduct of our business to acquire or increase an equity interest in our company."
• "To mitigate this operational risk, the Board of Directors approved the issuance of shares of Series B Preferred Stock."

Industry Context

StockSavvy.ai notes that Cosmos Health Inc.'s proxy statement reflects common corporate governance practices, including the election of directors, auditor ratification, and the implementation of equity incentive plans to align management and shareholder interests. The proposed Series B Preferred Stock issuance to aid in quorum is a measure to address potential challenges in shareholder engagement, a growing concern in the broader market.

Comparison to Industry Standards

• The proposed 2026 Equity Incentive Plan, with a maximum of 10,000,000 shares, is a standard mechanism for compensation and retention in the pharmaceutical and healthcare sectors. Companies like Pfizer and Merck also utilize similar equity plans, though the specific share pool size and award types vary based on company size and market capitalization.
• The ratification of RBSM LLP as the independent registered public accounting firm is a routine procedure. Larger pharmaceutical companies often engage Big Four accounting firms (Deloitte, PwC, EY, KPMG), while mid-cap and smaller companies may use firms like RBSM.
• The company's net losses are significant. For comparison, many early-stage biopharmaceutical companies operate at a loss for extended periods due to high R&D costs, but established pharmaceutical giants typically report profitability. Cosmos Health's financial performance, characterized by consistent net losses, places it in a more challenging financial position compared to industry leaders.
• The disclosure of related-party transactions, particularly with Doc Pharma, is a critical aspect of corporate governance. While common in many industries, the scale and nature of these transactions, including significant prepayments and a substantial allowance for doubtful accounts, warrant close scrutiny, especially when compared to the more transparent and arms-length transactions typical of larger, more established corporations.

Corporate Governance

Related Party Transactions

• Grigorios Siokas (CEO) provides non-interest bearing, no-term loans to the Company. As of December 31, 2025, the outstanding balance was $0. SkyPharm S.A. repaid $781,394 to Mr. Siokas through a set-off against salary and bonus liabilities.
• Dimitrios Goulielmos (former CEO) has a non-interest bearing loan with a principal balance of $11,971 as of December 31, 2024.
• Doc Pharma S.A. (CEO is son of Grigorios Siokas) has significant transactions: prepaid balances of $4,642,853 (2025) and $3,284,052 (2024) for inventory, licenses, and royalties. Accounts payable to Doc Pharma were $671,148 (2025) and $249,768 (2024). Receivables from Doc Pharma were $3,340,275 (2025) and $2,295,706 (2024), with a $1.7 million allowance for doubtful accounts. A loan receivable from Doc Pharma of $3,949,085 (as of Dec 31, 2025) has a full allowance for doubtful accounts recorded.
• Panagiotis Kozaris (employee of Cosmofarm S.A.) has advance payments of $194,215 (2025 & 2024) for share repurchases, with a full allowance for doubtful accounts recorded.
• Basotho Investment Limited (director is Panagiotis Kozaris) received 120,000 shares of common stock for services, valued at $0 in 2025 and $113,300 in 2024.
• Maria Kozari (daughter of Panagiotis Kozaris) owns Pharmacy & More. Net sales to Pharmacy & More were $460,016 (2025) and $414,443 (2024). Outstanding receivables were $1,721,143 (2025) and $1,183,429 (2024), with an $834,000 allowance for doubtful accounts. The company plans to acquire Pharmacy & More in fiscal year 2026.
• Accrued payables to officers include $894,336 to Grigorios Siokas, $420,000 to George Terzis, and $14,218 to Nikolaos Bardakis for unpaid salaries and bonuses as of December 31, 2025.

Stakeholder Impact

• Shareholders: The approval of the 2026 Equity Incentive Plan could dilute existing shareholders if new shares are issued, but it aims to improve long-term company performance. The Series B Preferred Stock issuance is intended to ensure quorum, preventing delays in corporate actions that could impact shareholder value.
• Employees: The 2026 Equity Incentive Plan provides opportunities for employees to receive equity awards, potentially increasing motivation and retention.
• Management: The equity plan and existing compensation structures are designed to incentivize management performance. However, the late filing of Section 16(a) reports by management raises concerns about compliance.
• Creditors: The company's ongoing net losses and significant allowances for doubtful accounts in related-party transactions could indirectly impact creditor confidence and the company's ability to meet its obligations.

Next Steps

• Stockholders are to vote on the proposed resolutions at the Annual Meeting on July 15, 2026.
• The company will file a Form 8-K with preliminary voting results within four business days after the Annual Meeting, followed by final results if necessary.
• The 2026 Equity Incentive Plan will become effective upon stockholder approval.
• The designation and issuance of Series B Preferred Stock will be filed with the Nevada Secretary of State after the Annual Meeting, subject to stockholder approval.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or significant strategic shifts that would warrant a buy or sell recommendation. While the equity incentive plan is a positive for future growth and retention, the ongoing net losses, compliance issues with Section 16 filings, and significant related-party transaction risks suggest a 'hold' position until clearer signs of financial improvement and stronger governance are demonstrated.

Keywords

Cosmos Health Inc., Proxy Statement, Annual Meeting, DEF 14A, Director Election, Equity Incentive Plan, Preferred Stock, Corporate Governance, SEC Filing